



CANCEROLGY CENTER OF LYON (CRCL) C³ CELL-DEATH AND CHILDHOOD CANCER LAB





Post-doctoral position _ Generation & *in-depth* characterization of organoid models as tools to identify the biological underpinnings of pediatric cancers.

Dr Laura Broutier

E-mail: laura.broutier@lyon.unicancer.fr

Keywords:

Pediatric Cancer, Organoids, Genetic engineering, CRISPR/Cas9

About the lab:

The establishment of cancer-derived organoids has recently begun to emerge as a prominent and promising tool to enhance our understanding of human cancers (*Broutier et al.*, nature protocols 2016 & Broutier et al., nature medicine 2017). However, such models have as yet not been developed for pediatric cancers. The research program that we develop in the "organoid group" of the C³ lab forms part of this perspective with the objective to elaborate innovative organoid models to address pediatric cancers specificities and complexity. We are affiliated to the Cancer Research Centre of Lyon (CRCL –INSERM U1052 / CNRS 5286) and to the Centre Léon Bérard's Pediatric hospital (IHOPE). The CRCL is amongst the most prestigious cancer research center in France and the IHOPE is a major reference pediatric cancer center. Our group is therefore composed of both researchers, clinicians and pathologists.

Position Highlight:

Starting on October 2019. Available for highly motivated post-doctoral fellow interested in conducting inter-disciplinary research using innovative *in-vitro* approaches to better understand the mechanisms of resistance to treatment in pediatric cancers, with a special focus on cell cooperation/competition mechanisms. Successful candidates will be part of a stimulating and collaborative scientific environment with cutting-edge instrumentation and facilities.

Length/Period:

The successful applicant will initially have a 1-year contract, with the possibility of extension (+2 years).

Salary

Salary will depend on candidate's experience.

Objectives:

The candidate should achieve the development of robust strategies & protocols to generate (i) organoids derived from pediatric healthy tissues and (ii) CRISPR-Cas9 modified organoids. Moreover, the candidate will use these organoids and tumoroids derived directly from pediatric tumoral samples (already available in the lab) and the Operetta CLS High-Content Analysis technology to explore mechanisms of cell cooperation/competition upon treatment. Finally, the candidate will be involved in writing reports, publications and grant applications.

Candidate profile:

- Strong academic background (evidenced by training and publications) is required, and notably an extensive experience
 in cancer biology, especially molecular and cellular assays, cytometry, immunohistochemistry, immunofluorescence
 techniques and subsequent data analysis. Moreover, the candidate should have a robust experience in primary and/or
 organoid culture and in genetic engineering technologies (lentivirus vectors and CRISPR/Cas9-mediated gene editing).
- The candidate should be highly self-motivated, with strong communication and interpersonal skills and the ability to work independently.
- Working experience with mice is desirable. Experienced with rhabdomyosarcoma, diffuse intrinsic pontine glioma and next generation sequencing data analysis will be considered a plus.

Elements to be provided for your application:

Interested candidates should send a single PDF file that includes a full curriculum vitae with publications, a short description of previous training & work experiences and the names, contact details and recommendation letters of 2 referees (former professor/advisor/mentor) to laura.broutier@lyon.unicancer.fr. Please indicate "POSTDOCTORAL POSITION_C3 TEAM" in the subject line.